154 related articles for article (PubMed ID: 33879087)
1. Characteristics and patient-reported outcomes associated with dropout in severely affected oncological patients: an exploratory study.
Gebert P; Schindel D; Frick J; Schenk L; Grittner U
BMC Med Res Methodol; 2021 Apr; 21(1):77. PubMed ID: 33879087
[TBL] [Abstract][Full Text] [Related]
2. Improving quality of life in cancer patients through higher participation and health literacy: study protocol for evaluating the oncological social care project (OSCAR).
Frick J; Schindel D; Gebert P; Grittner U; Schenk L
BMC Health Serv Res; 2019 Oct; 19(1):754. PubMed ID: 31655598
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
5. Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out.
Renovanz M; Hechtner M; Kohlmann K; Janko M; Nadji-Ohl M; Singer S; Ringel F; Coburger J; Hickmann AK
Neurooncol Pract; 2018 May; 5(2):129-138. PubMed ID: 31385978
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
7. Cross-Sectional Patient-Reported Outcome Measuring of Health-Related Quality of Life With Establishment of Cancer- and Treatment-Specific Functional and Symptom Scales in Patients With Penile Cancer.
Draeger DL; Sievert KD; Hakenberg OW
Clin Genitourin Cancer; 2018 Dec; 16(6):e1215-e1220. PubMed ID: 30201215
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
9. Home-based multidimensional survivorship programmes for breast cancer survivors.
Cheng KKF; Lim YTE; Koh ZM; Tam WWS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011152. PubMed ID: 28836379
[TBL] [Abstract][Full Text] [Related]
10. A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).
Marschner N; Wilke J; Reschke D; Kaiser F; Schmoor C; Grugel R; Boller E
J Med Econ; 2018 Sep; 21(9):920-929. PubMed ID: 29874105
[TBL] [Abstract][Full Text] [Related]
11. Identifying and handling unbalanced baseline characteristics in a non-randomized, controlled, multicenter social care nurse intervention study for patients in advanced stages of cancer.
Frick J; Gebert P; Grittner U; Letsch A; Schindel D; Schenk L
BMC Cancer; 2022 May; 22(1):560. PubMed ID: 35585571
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
13. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review.
Ratti MM; Gandaglia G; Alleva E; Leardini L; Sisca ES; Derevianko A; Furnari F; Mazzoleni Ferracini S; Beyer K; Moss C; Pellegrino F; Sorce G; Barletta F; Scuderi S; Omar MI; MacLennan S; Williamson PR; Zong J; MacLennan SJ; Mottet N; Cornford P; Aiyegbusi OL; Van Hemelrijck M; N'Dow J; Briganti A;
Eur Urol Oncol; 2022 Apr; 5(2):153-163. PubMed ID: 34785188
[TBL] [Abstract][Full Text] [Related]
14. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters S; Shaw AT; Besse B; Felip E; Solomon BJ; Soo RA; Bearz A; Gadgeel SM; Lin CC; Kao S; Seto T; Masters ET; Abbattista A; Clancy JS; Thurm H; Reisman A; Peltz G; Ross Camidge D
Lung Cancer; 2020 Jun; 144():10-19. PubMed ID: 32344248
[TBL] [Abstract][Full Text] [Related]
15. Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer.
Innominato PF; Komarzynski S; Palesh OG; Dallmann R; Bjarnason GA; Giacchetti S; Ulusakarya A; Bouchahda M; Haydar M; Ballesta A; Karaboué A; Wreglesworth NI; Spiegel D; Lévi FA
Cancer Med; 2018 Sep; 7(9):4396-4405. PubMed ID: 30088335
[TBL] [Abstract][Full Text] [Related]
16. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Prospective Cohort Study of the Patient-Reported Outcome Measures PRO-CTCAE and CAT EORTC QLQ-C30 in Major Abdominal Cancer Surgery (PATRONUS): A Student-Initiated German Medical Audit (SIGMA) Study.
; Mihaljevic AL
Ann Surg Oncol; 2021 Jun; 28(6):3075-3089. PubMed ID: 33683524
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
19. Adherence With Online Therapy vs Face-to-Face Therapy and With Online Therapy vs Care as Usual: Secondary Analysis of Two Randomized Controlled Trials.
Lippke S; Gao L; Keller FM; Becker P; Dahmen A
J Med Internet Res; 2021 Nov; 23(11):e31274. PubMed ID: 34730541
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
Mol L; Ottevanger PB; Koopman M; Punt CJ
Eur J Cancer; 2016 Oct; 66():138-43. PubMed ID: 27573427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
